Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmo nary surveillance program for patients undergoing highdose chemotherapy for leukemia or bone marrow trans plantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia.
Pulmonary failure is a major contributor to morbidity and mortality during marrow aplasia following high-dose antineoplastic therapy. For this reason, we initiated a pulmo nary surveillance program for patients undergoing highdose chemotherapy for leukemia or bone marrow trans plantation. As part of this program, bronchoscopy with BAL was performed prior to therapy and at the onset of granulocytopenia.
Thirty-three of the first 57 patients managed in this program developed some evidence of pulmonary complications. Twelve patients died in aplasia; all had pulmonary failure. Forty patients had clinically significant abnormalities on the bronchoscopy before treat ment, including 12 of 19 patients who had normal findings on chest x-ray films, physical examination, and pulmonary function testing, and no fever. Twenty-seven patients had clinically significant abnormal bronchoscopy or BAL at the onset of granulocytopenia. Thirteen patients required ad ditional bronchoscopy. No patient required an open lung biopsy. Pulmonary surveillance using bronchoscopy with BAL is useful in the detection of pulmonary disease prior to the initiation of and following high-dose antineoplastic therapy.
(Chest 1991; 99:105-11) ABMT = autologous bone marrow transplantation; 11!I = totalbody irradiation ulmonary complications of multiple etiologies are a major cause of morbidity during granulocytope nia after high-dose antineoplastic therapy for acute leukemia or bone marrow transplantation.'-2 Pulmo nary complications in this setting can be subtle in onset, but rapidly progressive, and can occur in a significant percentage of patients with no medical history or findings before aplasia to suggest high risk. Pulmonary failure has a high mortality, once estab lished, and is the most common proximate cause of death in these patients.2 Nevertheless, it is not clear that identifying the etiology of diffuse pulmonary disease after pulmonary compromise has developed results in a significant decrease in mortality.3-4 Con sequently, reduction in mortality related to this com plication may be possible only with early detection or prevention.
Bronchoscopy with BAL, a procedure which per mits visualization of the airways and samples approxi mately 106 alveoli,5'6 has a high diagnostic yield for infection and has been demonstrated to be safe to perform in severely immunosuppressed patients.7"
The likelihood that pathologic processes could be detected in the airways and alveoli prior to the development of pulmonary failure and that such determination might permit the prevention of pul monary compromise led us to initiate a pulmonary It seemed reasonable that bronchoscopy and BAL might be useful as a surveillance procedure to detect pathologicprocesses in the lung prior to the development of clinically significant disease. We, therefore, began to use bronchoscopy and BAL as a surveillance procedure in patients undergoing high-dose antineoplastic ther apy. We have now had an opportunity to review the first nine months of this experience, which forms the basis of this report.
MATERIALS ANDMETHODS

Pulmonary Surveillance Program
Our pulmonary surveillance program baseline consisted of a history and physical examination, PA and lateral chest roentgenograms, pulmonary laboratory spirometry and diffusing capacity determinations prior to treatment, and bronchoscopy with BAL. Portable AP chest x-ray film and l>edside spirometry were per formed three times weekly during hospitalization. The bronchos copy with BAL was repeated at the onset of granulocytopenia. Additional bronchoscopies were performed for clinical indications in 13 cases.
Rttients Studied
During the first nine months of our pulmonary surveillance program, 57 patients were managed at the University of Nebraska Medical Center with high-dose chemotherapy (with or without TBI) as part of marrow transplantation protocols or as remission induction for acute myelocytic leukemia. It was possible to perform bron choscopy and BAL prior to treatment on 53 of the 57 patients. One patient refused bronchoscopy, and three others were judged to need immediate institution of their antineoplastic therapy without any delay which might be required to organize a low-risk elective bronchoscopy or to permit time to recover from any morbidity of the procedure.
Bronchoscopy with BAL was performed at the time of onset of granulocytopenia in 47 of the 57 patients. The reasons for not having this second bronchoscopy included refusal (four patients), inability to tolerate the procedure (three patients), clinical assessment that risks outweighed benefits (two patients), and early death (one patient).
Fiberoptic Bronchoscopy and Bronchoalveolar Lavage
Flexible fiberoptic bronchoscopy was performed by staff pulmonologists with a bronchoscope (Olympus P-10 or equivalent). If the patient was having general anesthesia for bone marrow harvest immediately prior to chemotherapy, the bronchoscopy was per formed at the beginning of the procedure and was done through an in-place cuffed oral endotracheal tube. In all other cases, bronchos copy was performed transorally with topical lidocaine anesthesia. Atropine (0.6 mg) was routinely used as a premedication to dry upper airway secretions, and promethazine hydrochloride (Phenergan; 25 mg) and meperidine (Demerol) hydrochloride (25 mg) were given for sedation. Diazepam (Valium, 0 to 30 mg) was administered at the time of the procedure for additional sedation.
After a complete inspection of all visible bronchial segments, the bronchoscope was inserted into a gently wedged position. Sterile saline solution was then infused and immediately aspirated for a total of six 20-ml aliquots. In general, the lavage was repeated in three separate segments, and the corresponding aliquots from each site were pooled.
Processing of Lavage Fluids
The first aliquot returned from each lavage site (representing mostly bronchial material) and the next four aliquots (representing mostly alveolar material) were processed separately for cytology.12
The sixth aliquot was submitted for culture for bacterial, fungal, viral, and mycobacterial organisms. For cytologic analyses, "bron chial" and "alveolar" lavage fluids were filtered through loose nylon mesh to remove mucus, and the number of cells in each recovered aliquot was determined by hemacytometer.
Cytocentrifuge slides (Shandon), each containing 50,000 cells, were stained (Diff-Quick stain) for differential cell count13 and by a rapid Gomori methenamine silver stain to detect fungi and Pneumocystis."
In addition, a Millipore filter preparation was made with 100,000 cells" and stained by the Papanicolaou technique. The silver-stained slides were examined for fungal organisms and Pneumocystis carinii, while the Papanicolaou-stained material was evaluated for features indic ative of viral infection, diffuse alveolar damage, recurrent tumor, or other disorders.
Scoring of Abnormalities and Statistical Analysis
Anatomic findings were recorded at the time of bronchoscopy. These incuded endobronchial tumor, upper and lower airway obstruction, mucous plugging, hemorrhage, and moderate or severe bronchitis. "Anatomic" bronchitis was assessed visually be sepa rately scoring edema, friability, erythema, and secretions in each of the five lobes and the lingula. A second definition of bronchitis (and alveolitis) was the finding of an increased percentage of neutrophils in the lavage fluid. Greater than 15 percent neutrophils in the bronchial washing was scored as bronchitis (laboratory normal, 0 to 10 percent) and greater than 5 percent neutrophils in the alveolar washing (laboratory normal, 0 to 3 percent) was scored as alveolitis. Statistical comparisons were by x2 analysis.
RESULTS
Frequency of Pulmonary Compromise and Death
The relative frequency of diagnoses, the therapy administered, and other clinical characteristics of all 57 patients who received high-dose therapy during the period of this review are listed in Table 1 . Pulmonary complication was defined as new physical findings or deteriorating clinical status with significant new or progressive abnormalities on the chest x-ray film. Even when patients developed respiratory failure which was thought to be entirely secondary to failure of other organ systems, they were still scored as having pulmonary complications for the purpose of this anal ysis. No patient died without pulmonary complications by this definition. Pulmonary complications by this definition devel oped in 33 (58 percent) of the 57 patients in this series. These pulmonary complications were more common in patients receiving ABMT protocols (24/37; 65 per cent) than in patients receiving high-dose chemother apy for leukemia (9/20; 45 percent); however, mortality was greater in the patients with leukemia (6/20; 30 percent) than in the ABMT patients (6/37; 16 percent). Thus, the probability of dying of or with pulmonary complications for patients with leukemia was much higher than the probability of dying with or of pul monary complications for ABMT patients (6/9 vs 6/24; p<0.05). Within the ABMT group, those receiving TBI had a higher complication rate (13/17; 76 percent) than those not receiving TBI (11/20; 55 percent). In the ABMT group the six patients who died all had received TBI; there were no deaths in the ABMT patients who did not receive TBI (p<0.01).
Predictive Value of Findings before Treatment
We sought to determine whether admission pul monary function studies, history and physical exami nation, abnormalities on the chest x-ray films, or the presence or absence of fever predicted for any of the abnormal findings at pre-treatment bronchoscopy, as well as which, if any, of the clinical or bronchoscopic findings predicted for pulmonary complications or death during aplasia. Abnormal findings were fre quently observed at bronchoscopy or detected by BAL. Forty (75 percent) of the 53 patients undergoing pretreatment bronchoscopy and BAL had one or more abnormal finding (Table 2) .
Patients with abnormal initial bronchoscopic find ings had a significantly (p<0.01) greater risk of pul monary morbidity than patients with a normal pre treatment bronchoscopy. It was not possible to identify the specific findings of the pretreatment bronchoscopy and lavage which were the most important predictors of morbidity, but the numbers were small.
Twenty of the patients in the series had a normal chest x-ray film, a normal chest examination, no history of pulmonary compromise, and normal pulmonary function tests on admission. Nineteen of these patients had pretreatment bronchoscopy, and 12 of these had clinically significant visual findings or abnormalities in the BAL fluid (Table 3) . Clinically significant abnormalities amenable to therapy included Pcarinii, airway compromise, and fungal bronchitis. Clinical outcomes in the group of 20 patients with normal admission nonbronchoscopic pulmonary findings were compared with the outcomes of patients with abnormal admission chest x-ray films, pulmonary function stud ies, and physical examination in order to determine the value of noninvasive pulmonary evaluation to predict outcomes. Ten (50 percent) of the 20 patients with totally normal admission nonbronchoscopic pul monary findings developed pulmonary complications, while a slightly higher proportion (23/32; 72 percent) of patients with abnormal nonbronchoscopic pulmo nary findings developed pulmonary complications; however, five (25 percent) of the 20 patients with normal admission nonbronchoscopic pulmonary find ings died in aplasia, while only seven (19 percent) of the 37 patients with abnormal admission nonbron choscopic pulmonary findings died. Thus, in contrast to the predictive value of the pretreatment bronchos copy and BAL, there was no strong consistent corre lation of the pretreatment chest x-ray film or clinical status with subsequent pulmonary complications or death. 
Predictive Value of Findings before Aplasia
The frequency of abnormal findings on the bronchoscopy and BAL performed at the onset of aplasia (27/47; 57 percent) was still quite high, but was lower than the 75 percent abnormal finding rate from the pretreatment bronchoscopy and BAL. The distribu tion of findings at the pretreatment and preaplasia bronchoscopies was also not identical. Frequently the pretreatment abnormalities were resolved by the onset of marrow aplasia. The greatest difference in abnormal findings between the initial and second bronchoscopy was a result of the disappearance of neutrophils from the bronchial and alveolar washings following therapy; however, compared to the pretreatment bronchoscopy, specific abnormalities identified by the preaplasia bronchoscopy were more predictive of morbidity and mortality. Patients with persistent or new anatomic findings on bronchoscopy at the onset of aplasia had a significantly higher probability of pulmonary compli cations than patients whose bronchoscopic findings became or remained normal (11/12 vs 18/35; p<0.05). The finding of a culture positive for organisms other than normal upper-respiratory flora at the preaplasia bronchoscopy was strongly associated with a higher toxic death rate ( Table 2) . Five of eight patients with positive cultures died vs six of 39 patients whose preaplasia alveolar lavage fluid was sterile (p<0.01). The organisms isolated from the five patients who died (Candida albicans, C parapsilosis, Aspergillus, Pseudomonas aeroginosa, and Enterobacter aerogenes) all contributed significantly to their death.
Further Evaluation of Patients Developing Pulmonary Complications
Thirteen patients underwent an additional bron choscopy and BAL after the two surveillance bron choscopies for evaluation of new or progressive pul monary infiltrates developing prior to recovery from aplasia (Table 4) . Six of these studies confirmed per sistence of prior pathology, and seven studies identi- fied new pulmonary problems (diffuse alveolar hem orrhage in two, Aspergillus in two, P carinii in one, and budding yeast in one). Of the six patients in whom the procedure diagnosed a persistent pulmonary prob lem which was previously detected by a surveillance bronchoscopy, the diagnosis had been established six to 15 days prior to clinical deterioration. Thus, the surveillance bronchoscopy was able to identify clini cally significant disease prior to clinical manifestation, even though early diagnosis and treatment did not always prevent significant clinical progression.
Significant complications of the surveillance bron choscopy and BAL were not seen during this study. One patient in the study who was having a bronchos copy not as part of the surveillance program, but for evaluation of progressive interstitial infiltrate and severe arterial oxygen desaturation, suffered cardiac arrhythmias and further respiratory decompensation during the preparation for the procedure. This re sulted in the need for endotracheal intubation and mechanical ventilation.
No patient underwent open lung biopsy, a procedure with much higher associated morbidity. Consent for postmortem examination was obtained from the fam ilies of all 12 patients who died prior to granulocyte recovery. All patients were examined by uniform and extensive tissue sampling protocol at autopsy, including sampling of all major organs, all lobes of the lung, lymph node groups, and bone marrow for histologic examination. Cultures of the blood, lung, and spleen were taken for fungal, bacterial, and viral culture. In no patient was an etiology for pulmonary failure identified which was not documented prior to death. DISCUSSION High-dose antineoplastic chemotherapy has the po tential to improve cure rates for otherwise fatal malig nancy, but has a high morbidity and mortality.16"20 Improvements in supportive care will be required, especially as these treatment regimens become even more aggressive and are shown to be of benefit even to poor-risk patients. Pulmonary complications fre quently lead to pulmonary failure which is the major proximate cause of death in these patients. 2 In this series, we have observed that certain diagnoses, prior treatment history, TBI used in the high-dose treatment program, and possibly age predict for high risk of pulmonary complications and death.
Bronchoscopy with BAL has been shown to be useful in the evaluation of pulmonary decompensation in the immunocompromised host.3"9 In this review of our experience with surveillance bronchoscopy and BAL, we have confirmed that the procedure can be performed in such patients and can yield diagnostic and prognostic information not available by other clinical methods. Importantly, the information ob tained as a result of bronchoscopy could not be predicted by noninvasive assessments of pulmonary status, including history and physical examination, chest x-ray film, and pulmonary function tests. This supports the notion that the bronchoscopic and BAL information is complementary to the information obtained by these other methods. In addition, surveil lance bronchoscopies can be performed without high risk of serious morbidity or mortality. Finally, the information gained by the surveillance program, com bined with early bronchoscopy and BAL in the face of pulmonary problems, seems to preclude the need for open lung or transbronchial biopsies. The failure of the results of extensive postmortem studies to add to premortem understanding of pulmonary pathophysiology in any of the 12 patients who died with pulmo nary failure further supports this contention. Inas much as more invasive procedures can be avoided, BAL may also reduce morbidity, mortality, and cost.
The substantial morbidity and mortality from pul monary disease in this series confirms the observation of others and the need to improve diagnosis, preven tion, and supportive care strategies for these patients. The very high yield of unsuspected but clinically significant findings of the pretreatment broncho scopies in this series of very high-risk patients appears to be a step in this direction. The probability of finding abnormalities on surveillance bronchoscopy and BAL might have been lower in a lower risk population. Most of our patients had received previous chemo therapy or irradiation. Only 20 of 57 had normal chest x-ray film findings, pulmonary history and physical examination, and pulmonary function tests. This high frequency of abnormal clinical parameters is consis tent with the entire group of patients at high risk for pulmonary complications; however, unlike bronchos copy, none of the noninvasive studies alone or together was able to identify any subset of these patients which would subsequently suffer further pulmonary compro mise or death.
While surveillance bronchoscopy can identify clin ically significant abnormalities in the lung prior to these abnormalities becoming clinically manifest, this was not always sufficient to prevent poor outcomes. Of the 12 patients who died, three had at least one pathogen present on a surveillance bronchoscopy which persisted despite therapy and which contrib uted significantly to the patients death (Table 4 ; cases 29, 33, and 44). In general, pathologies discovered prior to cytotoxic therapy appear to have been man aged so that they did not result in morbidity or mortality, while pathologies persisting or discovered only at the onset of aplasia were more ominous. The information obtained by early diagnosis, therefore, is not sufficient to ensure a good outcome in the presence of high-dose chemotherapy. Until more effective sup portive care becomes available, early diagnosis may nevertheless have a positive impact in two ways. First, high-dose therapy may be delayed until after the resolution of a pathologic process in selected cases. In one patient in the present series with upper airway obstruction, for example, therapy was delayed until after an adequate airway had been guaranteed by tracheostomy. Secondly, cases at especially high risk can be identified and excluded as candidates for highdose therapy.
Bronchitis and alveolitis detected visually and by lavage were considered abnormalities in this study. We believe this to be the correct handling of this information, despite the fact that a clinically occult inflammatory process may not be of clinical signifi cance. It is possible that bronchitis or alveolitis contributed directly to pulmonary complications. Al ternatively, the inflammation may have been a mani festation of some other disease process which predis posed to complications. The identification of rare budding or nonbudding yeasts, particularly in the bronchial specimen, was generally not believed to be of clinical significance, owing to the high frequency of oropharyngeal yeasts that may contaminate the lavage specimen. When numerous budding yeasts were found in the alveolar aliquots, there was a high clinical suspicion of active Candida infection. When septated fungi were identi fied in the BAL specimen, there was significant concern that these may represent Aspergillus or other pathophysiologically significant molds. The identifi cation of viral cytopathic effects associated with cytomegalovirus or herpes simplex virus was almost always indicative of clinically significant disease. All of the cytologic findings require interpretation in the context of the visual findings and clinical setting.
It is not possible to determine how much redaction in pulmonary complications and mortality resulted from this pulmonary surveillance program, since clin ical management was adjusted to the findings. Exam ples included early institution of appropriate antibi otics for fungal, bacterial, and Pneumocystis infections, and aggressive management of airway ob struction. In fact, the lack of correlation between most of the clinically significant surveillance bronchoscopic findings and mortality suggests that these measures may have been effective in a number of cases.
In summary, the current study supports the utility of bronchoscopy with BAL as a part of aggressive pulmonary surveillance for patients receiving highdose antineoplastic therapy for leukemia or in bone marrow transplantation protocols. Clinically useful information can be obtained in a relatively noninvasive manner which appears to have little serious morbidity, even in this setting.
